Newsfeed

Bei diesem Bereich handelt es sich um eine mögliche Darstellungsform der Integration von Nachrichtenquellen mit Bezug zu börsennotierten Unternehmen.
Als Präsentationsebene fungiert ein Template, dass an Kurznachrichtenservices angelehnt ist, bei dem sich Nutzer einen schnellen Überblick über aktuelle Nachrichten verschaffen können. Die Detailansichten ermöglichen bei Interesse weitergehende Recherchen.

Dieser Newsfeed ist eine Zusammenstellung aktueller Nachrichten, die aus Direktanbindungen von TopTier NewsWire-Services mit Bezug zu börsennotierten Unternehmen stammen. Dieser Feed hier dient ausschließlich Demonstrationszwecken. Sektoren-spezifische Nachrichten, Public Relations sowie Produktinformationen können über die GICS Portale > Bereich Sektor-Intelligence abgerufen werden.

US01438T1060
Filter zurücksetzen
Do you already know our new terminal view? Click here.
FIGI: BBG0029H8ZF6
ALDX
Aldeyra Therapeutics Inc
GICS: Health Care · SECTOR: Healthcare · SUB-SECTOR: Biotechnology · THEMEFOLIO: $HLTH
NAME
Aldeyra Therapeutics Inc
ISIN
US01438T1060
TICKER
ALDX
MIC
XNAS
REUTERS
ALDX.OQ
BLOOMBERG
ALDX US
Di., 22.04.2025       Aldeyra Therapeutics
US01438T1060

NEW YORK, April 22, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Aldeyra Therapeutics, Inc. ("Aldeyra" or the "Company") (NASDAQ: ALDX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 22.04.2025       Aldeyra Therapeutics
US01438T1060

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Aldeyra Therapeutics, Inc. (“Aldeyra” or “the Company”) (NASDAQ: ALDX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or fail...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 17.04.2025       Aldeyra Therapeutics
US01438T1060

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced the appointment of Chip Clark to the company’s board of directors. “Chip possesses a wealth of experience leading innovative biotechnology...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 15.04.2025       Aldeyra Therapeutics
US01438T1060

NEW YORK, April 14, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Aldeyra Therapeutics, Inc. ("Aldeyra" or the "Company") (NASDAQ: ALDX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 10.04.2025       Aldeyra Therapeutics
US01438T1060

SAN FRANCISCO, April 10, 2025 /PRNewswire/ -- On April 3, 2025 investors in Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) saw the price of their shares crash over 70% after the company announced that it received a Complete Response Letter ("CRL") from the FDA for the resubmission of the New Drug Application ("NDA") of reproxalap, an investigational d...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 03.04.2025       Aldeyra Therapeutics
US01438T1060

Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) for potential violations of the federal securities laws. If you invested in Aldeyra Therapeutics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/aldeyra-t...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 03.04.2025       Aldeyra Therapeutics
US01438T1060

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced receipt of a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for the resubmission of the New Drug Application (ND...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 03.04.2025       Aldeyra Therapeutics
US01438T1060

Instrument ID [8902382] (137 - US01438T1060) suspended...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 10.03.2025       Aldeyra Therapeutics
US01438T1060

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the 2025 Leerink Partners Gl...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 04.02.2025       Aldeyra Therapeutics
US01438T1060

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at Oppenheimer’s 35th Annual He...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Mo., 02.12.2024       Aldeyra Therapeutics
US01438T1060

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in the Eyes Wide Open on Ophthalmology Panel at th...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 18.11.2024       Aldeyra Therapeutics
US01438T1060

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmitted New Drug Application (NDA) for topical ocular reproxalap, a first-in-class investigational new drug candidate, for the treatment of the signs and symptoms of dry eye disease. The FDA assigned...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 14.11.2024       Aldeyra Therapeutics
US01438T1060

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Jefferies London Healthc...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 31.10.2024       Aldeyra Therapeutics
US01438T1060

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced that Tomasz Stryjewski, M.D., Chief Medical Advisor - Retina, will present at the Disruptive Innovations Symposium during the Ocular Surger...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 03.10.2024       Aldeyra Therapeutics
US01438T1060

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced the resubmission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for topical ocular reproxalap, an investiga...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 05.09.2024       Aldeyra Therapeutics
US01438T1060

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 26th Ann...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 08.08.2024       Aldeyra Therapeutics
US01438T1060

Instrument ID [8902382] (137 - US01438T1060) suspended...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 15.04.2024       Aldeyra Therapeutics
US01438T1060

Philadelphia, Pennsylvania--(Newsfile Corp. - April 15, 2024) - Current Aldeyra shareholders who have continuously held Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) shares since prior to January 7, 2021 should click here: https://grabarlaw.com/the-latest/aldeyra-sahreholder-investigation/ to learn more. You can seek corporate reforms, the return of fu...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 29.03.2024       Aldeyra Therapeutics
US01438T1060

Philadelphia, Pennsylvania--(Newsfile Corp. - March 29, 2024) - Grabar Law Office is investigating claims on behalf of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) shareholders. The investigation concerns whether certain officers of Aldeyra have breached their fiduciary duties owed to the company.Current Aldeyra shareholders who have continuously held...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 27.03.2024       Aldeyra Therapeutics
US01438T1060

Philadelphia, Pennsylvania--(Newsfile Corp. - March 27, 2024) - Grabar Law Office is investigating claims on behalf of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) shareholders. The investigation concerns whether certain officers of FMC have breached their fiduciary duties owed to the company.Current Aldeyra shareholders who have continuously held Ald...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Mi., 20.03.2024       Aldeyra Therapeutics
US01438T1060

Philadelphia, Pennsylvania--(Newsfile Corp. - March 20, 2024) - Attention long-term shareholders of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX): A recently filed securities fraud class action complaint alleges that Aldeyra Therapeutics, through certain of its officers and directors, made materially false and misleading statements regarding the Compan...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 12.01.2024       Aldeyra Therapeutics
US01438T1060

Philadelphia, Pennsylvania--(Newsfile Corp. - January 12, 2024) - A recently filed securities fraud class action complaint alleges that Aldeyra Therapeutics, Inc. (NASDAQ: ALDX), through certain of its officers and directors, made materially false and misleading statements regarding the Company's business, operations, and prospects. Specifically t...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 08.01.2024       Aldeyra Therapeutics
US01438T1060

Philadelphia, Pennsylvania--(Newsfile Corp. - January 8, 2024) - A recently filed securities fraud class action complaint alleges that Aldeyra Therapeutics, Inc. (NASDAQ: ALDX), through certain of its officers and directors, made materially false and misleading statements regarding the Company's business, operations, and prospects. Specifically th...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 04.01.2024       Aldeyra Therapeutics
US01438T1060

Philadelphia, Pennsylvania--(Newsfile Corp. - January 4, 2024) - A recently filed securities fraud class action complaint alleges that Aldeyra Therapeutics, Inc. (NASDAQ: ALDX), through certain of its officers and directors, made materially false and misleading statements regarding the Company's business, operations, and prospects as pertains to th...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 29.09.2023       Aldeyra Therapeutics
US01438T1060

Los Angeles, California--(Newsfile Corp. - September 29, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Aldeyra Therapeutics, Inc. ("Aldeyra" or "the Company") (NASDAQ: ALDX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 28.09.2023       Aldeyra Therapeutics
US01438T1060

New York, New York--(Newsfile Corp. - September 28, 2023) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) between March 17, 2022 and June 20, 2023, both dates inclusive (the "Class Period"), of the important September 29, 2023 lead plaintiff deadline.SO WHAT: If...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 28.09.2023       Aldeyra Therapeutics
US01438T1060

New York, New York--(Newsfile Corp. - September 28, 2023) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Aldeyra Therapeutics, Inc. ("Aldeyra" or the "Company") (NASDAQ: ALDX) and certain of its officers.Class Definition:This lawsuit seeks to recover...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 28.09.2023       Aldeyra Therapeutics
US01438T1060

Los Angeles, California--(Newsfile Corp. - September 28, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Aldeyra Therapeutics, Inc. ("Aldeyra" or "the Company") (NASDAQ: ALDX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 27.09.2023       Aldeyra Therapeutics
US01438T1060

New York, New York--(Newsfile Corp. - September 27, 2023) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) between March 17, 2022 and June 20, 2023, both dates inclusive (the "Class Period"), of the important September 29, 2023 lead plaintiff deadline. SO WHAT: I...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 27.09.2023       Aldeyra Therapeutics
US01438T1060

Los Angeles, California--(Newsfile Corp. - September 27, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Aldeyra Therapeutics, Inc. ("Aldeyra" or "the Company") (NASDAQ: ALDX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 26.09.2023       Aldeyra Therapeutics
US01438T1060

Los Angeles, California--(Newsfile Corp. - September 26, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Aldeyra Therapeutics, Inc. ("Aldeyra" or "the Company") (NASDAQ: ALDX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 25.09.2023       Aldeyra Therapeutics
US01438T1060

Los Angeles, California--(Newsfile Corp. - September 25, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Aldeyra Therapeutics, Inc. ("Aldeyra" or "the Company") (NASDAQ: ALDX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
So., 24.09.2023       Aldeyra Therapeutics
US01438T1060

New York, New York--(Newsfile Corp. - September 23, 2023) - Pomerantz LLP announces that a class action lawsuit has been filed against Aldeyra Therapeutics, Inc. ("Aldeyra" or the "Company") (NASDAQ: ALDX), and certain officers. The class action, filed in the United States District Court for the District of Massachusetts, and docketed under 23-cv...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Sa., 23.09.2023       Aldeyra Therapeutics
US01438T1060

New York, New York--(Newsfile Corp. - September 22, 2023) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) between March 17, 2022 and June 20, 2023, both dates inclusive (the "Class Period"), of the important September 29, 2023 lead plaintiff deadline. SO WHAT: I...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 22.09.2023       Aldeyra Therapeutics
US01438T1060

Los Angeles, California--(Newsfile Corp. - September 22, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Aldeyra Therapeutics, Inc. ("Aldeyra" or "the Company") (NASDAQ: ALDX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 21.09.2023       Aldeyra Therapeutics
US01438T1060

Los Angeles, California--(Newsfile Corp. - September 21, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Aldeyra Therapeutics, Inc. ("Aldeyra" or "the Company") (NASDAQ: ALDX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 20.09.2023       Aldeyra Therapeutics
US01438T1060

Los Angeles, California--(Newsfile Corp. - September 20, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Aldeyra Therapeutics, Inc. ("Aldeyra" or "the Company") (NASDAQ: ALDX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 19.09.2023       Aldeyra Therapeutics
US01438T1060

Los Angeles, California--(Newsfile Corp. - September 19, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Aldeyra Therapeutics, Inc. ("Aldeyra" or "the Company") (NASDAQ: ALDX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 18.09.2023       Aldeyra Therapeutics
US01438T1060

Los Angeles, California--(Newsfile Corp. - September 18, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Aldeyra Therapeutics, Inc. ("Aldeyra" or "the Company") (NASDAQ: ALDX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 15.09.2023       Aldeyra Therapeutics
US01438T1060

New York, New York--(Newsfile Corp. - September 15, 2023) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) between March 17, 2022 and June 20, 2023, both dates inclusive (the "Class Period"), of the important September 29, 2023 lead plaintiff deadline.SO WHAT: If...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 15.09.2023       Aldeyra Therapeutics
US01438T1060

New York, New York--(Newsfile Corp. - September 15, 2023) - Pomerantz LLP announces that a class action lawsuit has been filed against Aldeyra Therapeutics, Inc. ("Aldeyra" or the "Company") (NASDAQ: ALDX), and certain officers. The class action, filed in the United States District Court for the District of Massachusetts, and docketed under 23-cv...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 15.09.2023       Aldeyra Therapeutics
US01438T1060

Los Angeles, California--(Newsfile Corp. - September 15, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Aldeyra Therapeutics, Inc. ("Aldeyra" or "the Company") (NASDAQ: ALDX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 14.09.2023       Aldeyra Therapeutics
US01438T1060

Los Angeles, California--(Newsfile Corp. - September 14, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Aldeyra Therapeutics, Inc. ("Aldeyra" or "the Company") (NASDAQ: ALDX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 13.09.2023       Aldeyra Therapeutics
US01438T1060

Los Angeles, California--(Newsfile Corp. - September 13, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Aldeyra Therapeutics, Inc. ("Aldeyra" or "the Company") (NASDAQ: ALDX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 12.09.2023       Aldeyra Therapeutics
US01438T1060

Los Angeles, California--(Newsfile Corp. - September 12, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Aldeyra Therapeutics, Inc. ("Aldeyra" or "the Company") (NASDAQ: ALDX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 12.09.2023       Aldeyra Therapeutics
US01438T1060

New York, New York--(Newsfile Corp. - September 11, 2023) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) between March 17, 2022 and June 20, 2023, both dates inclusive (the "Class Period"), of the important September 29, 2023 lead plaintiff deadline. SO WHAT: I...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 11.09.2023       Aldeyra Therapeutics
US01438T1060

Los Angeles, California--(Newsfile Corp. - September 11, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Aldeyra Therapeutics, Inc. ("Aldeyra" or "the Company") (NASDAQ: ALDX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 08.09.2023       Aldeyra Therapeutics
US01438T1060

Los Angeles, California--(Newsfile Corp. - September 8, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Aldeyra Therapeutics, Inc. ("Aldeyra" or "the Company") (NASDAQ: ALDX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 1...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 07.09.2023       Aldeyra Therapeutics
US01438T1060

Los Angeles, California--(Newsfile Corp. - September 7, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Aldeyra Therapeutics, Inc. ("Aldeyra" or "the Company") (NASDAQ: ALDX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 1...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 07.09.2023       Aldeyra Therapeutics
US01438T1060

New York, New York--(Newsfile Corp. - September 7, 2023) - Pomerantz LLP announces that a class action lawsuit has been filed against Aldeyra Therapeutics, Inc. ("Aldeyra" or the "Company") (NASDAQ: ALDX), and certain officers. The class action, filed in the United States District Court for the District of Massachusetts, and docketed under 23-cv-...
Zur Nachricht
Aldeyra Therapeutics
Charts & Research Termsheets Terminal
Permalink